Balaji Gandhi Sells 3,195 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 3,195 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $26.61, for a total value of $85,018.95. Following the completion of the sale, the chief financial officer now owns 148,509 shares of the company’s stock, valued at $3,951,824.49. The trade was a 2.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, October 15th, Balaji Gandhi sold 864 shares of Phreesia stock. The stock was sold at an average price of $21.03, for a total transaction of $18,169.92.

Phreesia Stock Up 5.3 %

Shares of Phreesia stock opened at $28.42 on Friday. The company has a current ratio of 1.74, a quick ratio of 1.77 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $29.16. The company has a market cap of $1.65 billion, a P/E ratio of -19.33 and a beta of 0.94. The company’s fifty day simple moving average is $22.70 and its two-hundred day simple moving average is $22.57.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. Phreesia’s revenue was up 16.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.58) earnings per share. Research analysts anticipate that Phreesia, Inc. will post -1.16 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on PHR. Robert W. Baird reduced their target price on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a research note on Tuesday, December 10th. Needham & Company LLC reissued a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research note on Tuesday, December 10th. Truist Financial raised their price target on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, KeyCorp boosted their price objective on Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday. Eleven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Phreesia presently has an average rating of “Buy” and an average price target of $30.64.

Institutional Investors Weigh In On Phreesia

Hedge funds have recently made changes to their positions in the company. International Assets Investment Management LLC lifted its position in Phreesia by 2,179.7% during the third quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after buying an additional 1,395 shares during the period. Lombard Odier Asset Management USA Corp bought a new position in shares of Phreesia in the 2nd quarter worth about $202,000. Point72 DIFC Ltd purchased a new position in Phreesia during the 2nd quarter valued at about $209,000. XTX Topco Ltd purchased a new position in Phreesia during the 3rd quarter valued at about $247,000. Finally, Hsbc Holdings PLC bought a new stake in Phreesia during the second quarter worth about $301,000. 92.10% of the stock is currently owned by institutional investors.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.